SHANGHAI LUMOSA THERAPEUTICS CO LTD has a total of 32 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2013. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are MEDIMMUNE LTD, IMCLONE LLC and KS BIOMEDIX LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | Australia | 3 | |
#3 | Canada | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Republic of Korea | 3 | |
#6 | Philippines | 3 | |
#7 | Brazil | 2 | |
#8 | Israel | 2 | |
#9 | Mexico | 2 | |
#10 | Taiwan | 2 | |
#11 | China | 1 | |
#12 | Japan | 1 | |
#13 | WIPO (World Intellectual Property Organization) | 1 | |
#14 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry | |
#4 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Heterocyclic compounds | |
#5 | Enzymes | |
#6 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Zhao Ming | 20 |
#2 | Peng Shiqi | 17 |
#3 | Jiang Xueyun | 9 |
#4 | Wang Yuji | 7 |
#5 | Wu Jianhui | 7 |
#6 | Feng Qiqi | 7 |
#7 | Chen Pei-Jiun | 4 |
#8 | Lee Shu-Hua | 4 |
#9 | Ming Zhao | 3 |
#10 | Feng Qi-Qi | 2 |
Publication | Filing date | Title |
---|---|---|
AU2019205128A1 | Single-domain antibody-cytosine deaminase fusion proteins | |
KR20160016863A | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof | |
TW201410708A | Novel compounds having thrombolytic, free radical scavenging and thrombus-targeting activities, and processes for preparation and uses thereof |